• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tapestry, Inc. Appoints Kevin Hourican and David Elkins to Board of Directors

    2/29/24 6:45:00 AM ET
    $BMY
    $SYY
    $TPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Food Distributors
    Consumer Discretionary
    Get the next $BMY alert in real time by email

    Tapestry, Inc. (NYSE:TPR), a house of iconic accessories and lifestyle brands consisting of Coach, Kate Spade, and Stuart Weitzman, today announced that Kevin Hourican, President and Chief Executive Officer of Sysco Corporation (NYSE:SYY), and David Elkins, Executive Vice President and Chief Financial Officer of Bristol Myers Squibb (NYSE:BMY), have been appointed to the Company's Board of Directors. The appointments of Mr. Hourican and Mr. Elkins to the Board bring the membership to eleven, including ten independent directors.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229220934/en/

    Kevin Hourican (Photo: Business Wire)

    Kevin Hourican (Photo: Business Wire)

    Joanne Crevoiserat, Chief Executive Officer of Tapestry, Inc., said, "We are pleased to welcome Kevin and David to our Board – two proven leaders in driving global growth and transformation at scale. I am confident that their experience and insights will be invaluable, particularly at this exciting time in our company's history. I look forward to working with them as we execute our strategic agenda and position Tapestry as a leader in innovation and shareholder returns for years to come."

    Anne Gates, Chair of the Board of Tapestry, Inc., added, "We are delighted to have two exceptional leaders join our Board. Kevin and David bring significant strategic and financial expertise, with successful track records of delivering innovation and disciplined global growth, including deep M&A experience. Their appointments further strengthen our Board, and I look forward to the positive impact they will have on our company and its future."

    Kevin Hourican

    Kevin Hourican is the President and Chief Executive Officer of Sysco Corporation, the global leader in selling, marketing and distributing food products to restaurants, healthcare and educational facilities, lodging establishments and other customers who prepare meals away from home. Kevin has served as Sysco's President and CEO and as a member of its Board of Directors since February 1, 2020, leading the Company's large-scale, customer-focused and growth-related transformation, aimed at further improving the way Sysco supports its customers and accelerating profitable sales growth. Prior to Sysco, he served as Executive Vice President of CVS Health Corporation, a premier health innovation company, and President of CVS Pharmacy, overseeing CVS Health's $85 billion retail business, including 9,900 retail stores and over 200,000 employees, as well as merchandising, marketing, supply chain, real estate, front store operations, pharmacy growth, pharmacy clinical care and pharmacy operations. Prior to joining CVS Health, Kevin held executive leadership roles at Macy's, most recently serving as Senior Vice President, Regional Director of Stores, responsible for the management of 110 department stores in the Mid-Atlantic region. Kevin holds an undergraduate degree in Economics and a master's degree in Supply Chain Management, both from The Pennsylvania State University.

    Upon his appointment, Kevin Hourican said, "I am excited to be joining the Board of Directors of Tapestry, an innovative, purpose-driven company with a consumer-led approach to building enduring brands. I look forward to working with the Board and the talented Tapestry team, supporting the organization as it expands its global reach, driving customer engagement and enhanced shareholder returns."

    David Elkins

    David Elkins is the Executive Vice President and Chief Financial Officer of Bristol Myers Squibb (BMS), a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. In his current role, David has responsibility for Global Business Operations, which includes Business Development, Business Insights & Analytics, Global Finance, and Strategic Sourcing & Procurement. David joined BMS as a result of the acquisition of Celgene where he was Executive Vice President & Chief Financial Officer. Prior to Celgene, he served as Chief Financial Officer for Johnson & Johnson's (J&J) Consumer Products, Medical Devices, and Corporate Functions. Before J&J, he served as Executive Vice President & CFO of Becton, Dickinson & Company, a leading global medical device company, and held roles of increasing responsibility at AstraZeneca from 1995 to 2008. He began his career in finance at The Boeing Company. David earned his B.S. degree in Economics from the University of Delaware, an M.S. degree from the University of Pennsylvania, and an M.B.A. from Drexel University.

    Upon his appointment, David Elkins stated, "I'm honored to join Tapestry's Board of Directors at this important chapter in the company's history. Tapestry is home to iconic brands, with a track record of operational excellence. I look forward to working with the Board and leadership team to deliver on its strategic and financial growth agenda to drive sustainable growth and shareholder value."

    About Tapestry, Inc.

    Our global house of brands unites the magic of Coach, kate spade new york and Stuart Weitzman. Each of our brands are unique and independent, while sharing a commitment to innovation and authenticity defined by distinctive products and differentiated customer experiences across channels and geographies. We use our collective strengths to move our customers and empower our communities, to make the fashion industry more sustainable, and to build a company that's equitable, inclusive, and diverse. Individually, our brands are iconic. Together, we can stretch what's possible. To learn more about Tapestry, please visit www.tapestry.com. For important news and information regarding Tapestry, visit the Investor Relations section of our website at www.tapestry.com/investors. In addition, investors should continue to review our news releases and filings with the SEC. We use each of these channels of distribution as primary channels for publishing key information to our investors, some of which may contain material and previously non-public information. The Company's common stock is traded on the New York Stock Exchange under the symbol TPR.

    This information to be made available in this press release may contain forward-looking statements based on management's current expectations. Forward-looking statements include, but are not limited to, statements regarding long term performance, statements that can be identified by the use of forward-looking terminology such as "may," "will," "can," "should," "expect," "expectation," "potential," "intend," "estimate," "continue," "project," "guidance," "forecast," "outlook," "commit," "anticipate," "goal," "leveraging," "sharpening," transforming," "creating," accelerating," "enhancing," "innovation," "drive," "targeting," "assume," "plan," "progress," "confident," "future," "uncertain," "on track," "achieve," "strategic," "growth," "view," "vision," "we can stretch what's possible," "futurespeed," or comparable terms. Future results may differ materially from management's current expectations, based upon a number of important factors, including risks and uncertainties such as the impact of economic conditions, recession and inflationary measures, the impact of the Covid-19 pandemic, risks associated with operating in international markets and our global sourcing activities, the ability to anticipate consumer preferences and retain the value of our brands, including our ability to execute on our e-commerce and digital strategies, the ability to successfully implement the initiatives under our 2025 growth strategy, the effect of existing and new competition in the marketplace, our ability to control costs, the effect of seasonal and quarterly fluctuations on our sales or operating results; the risk of cybersecurity threats and privacy or data security breaches, our ability to protect against infringement of our trademarks and other proprietary rights, the impact of tax and other legislation, the risks associated with potential changes to international trade agreements and the imposition of additional duties on importing our products, our ability to achieve intended benefits, cost savings and synergies from acquisitions including our proposed acquisition of Capri Holdings Limited ("Capri"), the anticipated impact of the proposed acquisition of Capri on the combined company's business and future financial and operating results, the anticipated closing date for the proposed acquisition of Capri, the satisfaction of the conditions precedent to consummation of the proposed acquisition of Capri, including the ability to secure regulatory approvals on the terms expected, at all or in a timely manner, the impact of pending and potential future legal proceedings, and the risks associated with climate change and other corporate responsibility issues, etc. In addition, purchases of shares of the Company's common stock will be made subject to market conditions and at prevailing market prices. Please refer to the Company's latest Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission for a complete list of risks and important factors. The Company assumes no obligation to revise or update any such forward-looking statements for any reason, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240229220934/en/

    Get the next $BMY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMY
    $SYY
    $TPR

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    8/5/2025$42.00Outperform → Neutral
    Daiwa Securities
    Tapestry Inc.
    $TPR
    7/29/2025$115.00Buy → Neutral
    BofA Securities
    Tapestry Inc.
    $TPR
    6/12/2025$100.00Hold → Buy
    TD Cowen
    Sysco Corporation
    $SYY
    5/23/2025$78.00Neutral
    Citigroup
    Tapestry Inc.
    $TPR
    5/8/2025$90.00Equal-Weight → Overweight
    Morgan Stanley
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    Tapestry Inc.
    $TPR
    2/18/2025$110.00Neutral → Buy
    Redburn Atlantic
    More analyst ratings

    $BMY
    $SYY
    $TPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    4/29/25 6:14:13 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/21/25 7:09:34 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/19/25 7:19:54 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $SYY
    $TPR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $SYY
    $TPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Paul Alison Kenney was granted 100 shares, increasing direct ownership by 1% to 9,764 units (SEC Form 4)

    4 - SYSCO CORP (0000096021) (Issuer)

    9/30/25 5:08:52 PM ET
    $SYY
    Food Distributors
    Consumer Discretionary

    Director Glasscock Larry C was granted 320 shares, increasing direct ownership by 0.33% to 98,161 units (SEC Form 4)

    4 - SYSCO CORP (0000096021) (Issuer)

    9/30/25 5:07:04 PM ET
    $SYY
    Food Distributors
    Consumer Discretionary

    Director Dibadj Ali was granted 336 shares, increasing direct ownership by 3% to 13,089 units (SEC Form 4)

    4 - SYSCO CORP (0000096021) (Issuer)

    9/30/25 5:05:05 PM ET
    $SYY
    Food Distributors
    Consumer Discretionary

    $BMY
    $SYY
    $TPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bristol-Myers downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Bristol-Myers from Outperform to Neutral and set a new price target of $42.00

    8/5/25 7:09:09 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tapestry downgraded by BofA Securities with a new price target

    BofA Securities downgraded Tapestry from Buy to Neutral and set a new price target of $115.00

    7/29/25 7:37:22 AM ET
    $TPR
    Apparel
    Consumer Discretionary

    Tapestry upgraded by TD Cowen with a new price target

    TD Cowen upgraded Tapestry from Hold to Buy and set a new price target of $100.00

    6/12/25 7:38:52 AM ET
    $TPR
    Apparel
    Consumer Discretionary

    $BMY
    $SYY
    $TPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease

    Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the potential of anti-MTBR tau to be an important treatment option for patients with Alzheimer's disease Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer's disease. Fast Track Designation is intended to facilitate the development and expedite the review of inve

    10/1/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    REPEAT – Sysco To Go and Latin Restaurant Weeks Celebrate Houston's Culinary Roots with Hispanic Heritage Night

    HOUSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- On Monday, September 29, Sysco To Go and Latin Restaurant Weeks will host Hispanic Heritage Night, celebrating the flavors, traditions, and people behind Houston's vibrant Latin food scene. Houston is one of America's most diverse food cities, and its Latin culinary heritage is central to that identity. Harris County boasts the second-highest number of Mexican restaurants in the U.S., and many food historians trace the birthplace of the fajita—a now-beloved national dish—to Houston. This event will feature tastings from Latin American food vendors—including samples from Goya—live music, and conversations with local restaurateurs about the challe

    9/29/25 11:00:00 AM ET
    $SYY
    Food Distributors
    Consumer Discretionary

    Sysco To Go and Latin Restaurant Weeks Celebrate Houston's Culinary Roots with Hispanic Heritage Night

    HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- On Monday, September 29, Sysco To Go and Latin Restaurant Weeks will host Hispanic Heritage Night, celebrating the flavors, traditions, and people behind Houston's vibrant Latin food scene. Houston is one of America's most diverse food cities, and its Latin culinary heritage is central to that identity. Harris County boasts the second-highest number of Mexican restaurants in the U.S., and many food historians trace the birthplace of the fajita—a now-beloved national dish—to Houston. This event will feature tastings from Latin American food vendors—including samples from Goya—live music, and conversations with local restaurateurs about the challe

    9/25/25 11:00:00 AM ET
    $SYY
    Food Distributors
    Consumer Discretionary

    $BMY
    $SYY
    $TPR
    SEC Filings

    View All

    SEC Form DEFA14A filed by Tapestry Inc.

    DEFA14A - TAPESTRY, INC. (0001116132) (Filer)

    9/26/25 4:21:12 PM ET
    $TPR
    Apparel
    Consumer Discretionary

    SEC Form DEF 14A filed by Tapestry Inc.

    DEF 14A - TAPESTRY, INC. (0001116132) (Filer)

    9/26/25 4:19:56 PM ET
    $TPR
    Apparel
    Consumer Discretionary

    Tapestry Inc. filed SEC Form 8-K: Leadership Update

    8-K - TAPESTRY, INC. (0001116132) (Filer)

    9/19/25 4:16:48 PM ET
    $TPR
    Apparel
    Consumer Discretionary

    $BMY
    $SYY
    $TPR
    Leadership Updates

    Live Leadership Updates

    View All

    Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

    Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team Samit Hirawat, M.D., Executive Vice President, to step down from his role on August 1 and will depart BMS on November 1 Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company's early-stage and late-stage product development across all therapeutic areas. "We are thrilled to welcome Cristian to Bristol Myers Squibb," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "His d

    7/25/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sysco celebrates expansion with grand opening of Sysco Tampa Bay

    PLANT CITY, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Today, Sysco Corporation, the leading global foodservice distribution company, is inviting media to attend a press conference and tour celebrating the grand opening of our newest distribution center, Sysco Tampa Bay. WHAT: Sysco Tampa Bay grand opening, ribbon-cutting, press conference and tourTIME AND DATE: 9:30 a.m. EST on July 24, 2025WHERE: 475 Charlie Taylor Road, Plant City, Fla., 33566KEY SPEAKERS: Sysco Chairman and CEO Kevin HouricanFlorida State Sen. Jay CollinsPlant City Mayor Nate KiltonFlorida State Commerce Department representative Madison LawsonSysco Region President Jane GroutRSVP AND QUESTIONS: [email protected] Sysco in

    7/22/25 8:40:15 AM ET
    $SYY
    Food Distributors
    Consumer Discretionary

    Sysco Opens Second Sysco To Go Store in the Heart of the City's Diverse Culinary Scene

    HOUSTON, July 21, 2025 (GLOBE NEWSWIRE) -- Sysco Corporation, global leader in foodservice distribution, invites media to join it in a grand opening celebration of its second Sysco To Go store —a retail store designed to meet the needs of independent restaurants, food trucks, caterers and small businesses in the heart of Houston's medical, sports and entertainment hub. Strategically located in central Houston near various businesses and foodservice establishments, Sysco To Go expands access to well-priced, quality products – from Mexican and Pan-Asian to American bar & grill favorites.The grand opening event will feature a ribbon-cutting ceremony, product samples and opportunities to co

    7/21/25 12:01:00 PM ET
    $SYY
    Food Distributors
    Consumer Discretionary

    $BMY
    $SYY
    $TPR
    Financials

    Live finance-specific insights

    View All

    Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

    Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristo

    9/19/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Announces Dividend

    Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on November 3, 2025, to stockholders of record at the close of business on October 3, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on December 1, 2025, to stockholders of record at the close of business on November 4, 2025. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discov

    9/17/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tapestry, Inc. Introduces Its "Amplify" Growth Strategy and Long-Term Financial Targets

    Expects to Drive Continued Durable, Profitable Growth and Significant Shareholder Returns Over the Three-Year Planning Horizon Initiates Outlook for Mid-Single Digit Revenue Increase, Strong Margin Expansion, and Low-Double-Digit Diluted EPS Growth in Fiscal Years 2027 and 2028; Maintains Growth Outlook for Fiscal Year 2026 Plans to Return $4 Billion in Capital to Shareholders Through Fiscal Year 2028 via Share Repurchases and Dividends, Supported by the Company's Robust Free Cash Flow Announces New $3 Billion Share Repurchase Authorization Tapestry, Inc. (NYSE:TPR), a house of iconic accessories and lifestyle brands, today is hosting its 2025 Investor Day in New York City. At

    9/10/25 6:45:00 AM ET
    $TPR
    Apparel
    Consumer Discretionary

    $BMY
    $SYY
    $TPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sysco Corporation

    SC 13G/A - SYSCO CORP (0000096021) (Subject)

    11/12/24 5:52:37 PM ET
    $SYY
    Food Distributors
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Tapestry Inc.

    SC 13G/A - TAPESTRY, INC. (0001116132) (Subject)

    11/12/24 10:34:15 AM ET
    $TPR
    Apparel
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Sysco Corporation

    SC 13G/A - SYSCO CORP (0000096021) (Subject)

    11/4/24 1:52:26 PM ET
    $SYY
    Food Distributors
    Consumer Discretionary